Krka believes that its financial results for the first six months of the year “are encouraging and that we will meet our plans for 2024,” after its prescription Pharmaceuticals sales rose by 9% to €823.4m ($897m), helping towards a “strong group EBITDA margin of 28.8%, which is well above the strategic guidance.”
The Slovenian firm enjoyed increased revenues in all six of its geographic business segments, including in its key East Europe...








